The Next Wave therapy chair is cleared by the U.S. Food and Drug Administration as a class II medical device (FDA 510(k)). The FDA allows three claims: tension relief, increase of blood circulation and relief of pain.
The Next Wave Physioacoustic electronic device is also medically tested by the BSI in the U.K. The Physioacoustic technology is safe and non-invasive.
Since the 1990´s of the last century several studies have been done on the effects of Physioacoustic therapy in various symptoms and diseases.
- High blood pressure
- Chronic back and neck pain
- Functional capacity, blood circulation
- Multiple Sclerose
- Residential aged care
- Total knee replacement